Outcomes of Lymphadenectomy for Early-Stage Mucinous Ovarian Cancer: A
Retrospective Study Based on Surveillance, Epidemiology, and End Results
(SEER) Database
Abstract
Objective: To evaluate the efficacy of lymphadenectomy for early-stage
primary mucinous ovarian cancer (MOC). Design: Retrospective observation
study Setting: Surveillance, Epidemiology, and End Results (SEER)
database for 2000-2018 Population or sample: The study population
comprised 1848 patients with early-stage MOC Methods: MOCs were divided
into two groups according to lymphadenectomy. Propensity score matching
were performed to correct for deviations. Independent risk factors for
overall survival (OS) were determined by multivariate analysis using Cox
regression. The role of lymphadenectomy was performed in different
populations by stratified analysis applying interaction analysis. OS was
calculated by Kaplan-Meier curves and compared by log-rank test. Main
outcome measures: Overall survival Results: In the study, almost 65.8%
(n = 1214/1848) experienced lymphadenectomy. Lymphadenectomy (HR =
0.692, 95% CI = 0.516-0.927, P = 0.009), age at diagnosis (HR = 3.028,
95% CI = 1.477-6.208, P = 0.002), and laterality (HR = 2.013, 95% CI =
1.145-3.54, P = 0.015) were found to be associated with OS. The role of
lymphadenectomy varied by age group and tumor laterality, and the 5-year
survival rates of patients with bilateral tumors who had experienced
lymphadenectomy with sampling and dissection, or for MOC over age 50 and
were higher than that of patients who did not undergo lymphadenectomy.
Conclusion: Lymphadenectomy with sampling and dissection has little
impact on OS in patients with early MOC. Lymph node therapy can be
discontinued in patients younger than 50 years, and lymph node sampling
is recommended for patients older than 50 years or with bilateral
tumors.